Medicare's Two Biggest Moves in Cardiometabolic Care Signal What's Next

Most years, Medicare policy moves slowly enough that healthcare organizations can plan around it a year or two out. 2026 has not been one of those years. Within a five-day span in early July, CMS activated two different mechanisms touching the same population: the Medicare GLP-1 Bridge and the ACCESS Model. Neither one is small, and together they tell a more useful story than either does alone.

Here is what each one actually does, why the combination matters more than the individual headlines, and what it means for any organization trying to build a cardiometabolic care program in the years ahead.

The Market Signal: CMS Rethinks Payment for Chronic Care with ACCESS

The ACCESS Model is a structural shift most coverage undersells: a ten-year CMS Innovation Center model that pays organizations a flat, per-patient annual amount to manage a chronic condition, with a meaningful share of that payment tied to whether the patient's numbers actually improved.

That is a real departure from how Medicare fee-for-service has historically worked. Original Medicare pays for activity: a visit, a lab, a monitoring device reading. It does not ask whether a patient's blood pressure or A1c actually moved. Chronic cardiometabolic disease management is inherently longitudinal, built on coaching, medication titration, and sustained behavior change over months and years, and that mismatch between how Medicare pays and what this population needs is exactly the gap CMS built the Innovation Center to test solutions for.

ACCESS covers four clinical tracks, including an early cardio-kidney-metabolic track and a broader cardio-kidney-metabolic track that together map closely onto the population organizations serve through weight management and related cardiometabolic programs. CMS says the model focuses on conditions affecting more than two-thirds of people with Medicare, which gives a sense of how central this shift is meant to be, not a peripheral pilot.

Enrollment is also open to more than traditional provider organizations. CMS has already accepted nearly 200 organizations into the first cohort, and several have no history serving Medicare beneficiaries at all, including a number of familiar consumer health and digital platforms.

That is the real signal. Medicare is building a durable payment lane for technology-enabled, outcomes-based chronic care, and it is inviting a wider range of organizations to build in that lane than fee-for-service ever did.

The Immediate Proof Point: The Medicare GLP-1 Bridge

If ACCESS shows where Medicare is headed, the Medicare GLP-1 Bridge is evidence that the shift is already generating real, near-term demand.

The Bridge gives eligible Part D beneficiaries access to FDA-approved GLP-1 therapy for weight management at a flat $50 monthly copay, a first for Medicare obesity coverage at this scale.

Estimates of exactly how many beneficiaries qualify have narrowed considerably as the program's eligibility rules have been worked through. CMS's own Medicare director has pointed to "single-digit millions" at launch, and a KFF analysis of 2023 claims data puts the number closer to 3.8 million once the program's specific exclusions are applied. That is a smaller, more clinically defined population than early estimates suggested, and it raises the stakes on eligibility screening and prior authorization. In a program this size, losing a patient to administrative friction is not a rounding error.

The Bridge operates outside Part D, with a single central processor handling prior authorization and claims, and it runs through December 31, 2027 while CMS uses the utilization data it generates to inform what a longer-term Medicare GLP-1 coverage pathway eventually looks like.

Bridge and ACCESS are not the same program, and they should not be treated as if one contains the other. Bridge is about affording the drug. ACCESS is about paying for the ongoing management of the condition. But a beneficiary can plausibly sit inside both at once: a patient using a Bridge-covered GLP-1 while a separate organization is paid through ACCESS to manage the hypertension or prediabetes that travels alongside it. Related signals, not a single program.

What makes Bridge worth watching closely is that CMS built the program explicitly as a data-collection window, gathering real-world utilization and outcomes data ahead of whatever coverage model comes next.

Organizations building strong operational infrastructure around Bridge now are the ones with a real claim to what's next.

What the Two Signals Point to for Cardiometabolic Care

Read side by side, ACCESS and the Bridge describe the same destination from two different directions: technology-enabled care, tied to outcomes, sustained over time rather than delivered in a single encounter, and increasingly open to organizations that were never part of traditional Medicare delivery.

That is a meaningfully different market than the one most cardiometabolic programs were built for even two years ago. A program designed around a single prescribing encounter is not built for a payment model that only releases the full reimbursement when a population-level outcome threshold is met. A program built purely around commercial cash-pay economics is not built for a Bridge population with its own eligibility rules, PA sequencing, and disclosure requirements.

Why Medicare's New Models Are Hard to Operationalize

None of this is simple to operationalize, and that is the part that gets lost in most coverage of either program.

Standing up care that actually works inside these models means managing a distributed clinician network licensed across states, building intake and eligibility logic specific to each program's rules, sequencing prior authorization correctly so patients are not stuck between a denial and an approval, retrieving and using a patient's full clinical history rather than starting from a blank intake form, and doing all of it in a way that stays financially sustainable at population scale rather than just at pilot scale.

That is a compliance-sensitive clinical build. It is not something most organizations can stand up by adding a digital front end to an existing workflow, and it is not something that gets solved by treating Medicare as one more distribution channel for an existing commercial program.

Cardiometabolic Infrastructure at Medicare Scale

This is the infrastructure problem Wheel has spent years building for. Wheel's AI-first platform, Wheel Horizon™, ingests and normalizes patient health context, routes patients to appropriately licensed clinicians, manages state-by-state compliance, sequences pharmacy and prior authorization workflows, retrieves historical clinical documentation, and supports patients over the full arc of a chronic condition rather than a single visit.

That infrastructure already powers Medicare Bridge-ready programs today and is designed to support organizations participating in ACCESS as that model scales. In the first half of 2026 alone, Wheel powered 300,000 branded GLP-1 encounters, more than 50,000 of them for adults aged 60 and older, backed by a clinician network representing more than 20,000 active state licenses and a 70% patient follow-up rate in weight management programs, well above what most point-solution programs see.

That infrastructure is already live in market rather than theoretical, with partners across retail, digital health, and payer segments building Medicare-ready programs on it today.

"Our customers aren't investing in infrastructure for a single Medicare initiative. They're investing in the capabilities they'll need for today's cardiometabolic care and for where healthcare is going next. Clinical infrastructure that combines tech, data, and care delivery is just not optional anymore for sustainable success at scale."

- Michelle Davey, CEO, Wheel

What This Means for Your Virtual Care Program

Whether an organization's most immediate question is Bridge readiness or ACCESS participation, the underlying question is the same: can our clinical and operational infrastructure actually support a technology-enabled, outcomes-based care model at the scale Medicare is now building toward? That's a harder question than most programs were designed to answer, but it's worth asking now while both models are still early enough to get the infrastructure right, rather than retrofitting the tech once they're locked in.

Discover what Medicare's shift toward outcomes-based chronic care means for your cardiometabolic program. Talk to Wheel